APOH and COVID-19: A recently published study of 122 COVID-19 patients determined the prevalence of IgG and IgM aCL in 13.4 and 2.7% and IgG and IgM anti-β2-GPI in 6.3 and 7.1% cases, which is significantly less frequent compared to the prevalence reported in APS patients (18).